Wirksamkeit und Sicherheit von magensaftresistentem Phosphatidylcholin-Granulat (LT-02) in der Remissionserhaltung bei Colitis ulcerosa Patienten mit zuvor ungenügendem Ansprechen auf Mesalazin: eine randomisierte, doppelblinde, Plazebo-kontrollierte Studie
Axel Dignaß(Goethe University Frankfurt), Walter Reinisch(Medical University of Vienna), Е. Б. Авалуева(North-Western State Medical University named after I.I. Mechnikov), Peter A. Ubel(Duke University), Klaus Fellermann(Apple (Israel)), Piotr Walczak(University of Maryland, Baltimore), Jost Langhorst(ThyssenKrupp (Germany)), Marek Kowalski, M. Horyński(Sopot University of Applied Science), Monther Bajbouj(TUM Klinikum), Wolfgang Stremmel(University Hospital Heidelberg), Olga Oleynik, H Heinemann(Dr Falk Pharma (Germany)), Jürgen M. Stein(Unknown), Roland Greinwald(Dr Falk Pharma (Germany)), L. S. Bilianskyi(Bogomolets National Medical University), Peter Armerding(Pathodiagnostik Berlin), Rudolf Müller(University of Hohenheim), Tanja Kühbacher(University Hospital Schleswig-Holstein)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis
|New England Journal of Medicine|1985|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969